Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AdAlta Ltd. ( (AU:1AD) ) has issued an update.
AdAlta Ltd has lodged an application with the ASX for quotation of 240 million new fully paid ordinary shares and 120 million options expiring in June 2028, all to be issued on 30 January 2026. The substantial new equity and options issuance, previously flagged in an earlier market filing, will expand AdAlta’s listed capital base and may provide additional funding flexibility, with potential implications for existing shareholder dilution and the company’s positioning for future clinical and commercial milestones.
The most recent analyst rating on (AU:1AD) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on AdAlta Ltd. stock, see the AU:1AD Stock Forecast page.
More about AdAlta Ltd.
AdAlta Ltd is an Australia-listed company on the ASX under the code 1AD. While this filing does not describe its business, AdAlta operates in the life sciences sector and is known for developing next‑generation therapeutic products based on its proprietary technology platform.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$11.48M
Learn more about 1AD stock on TipRanks’ Stock Analysis page.